<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Humacyte Inc — News on 6ix</title>
    <link>https://6ix.com/company/humacyte-inc</link>
    <description>Latest news and press releases for Humacyte Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/humacyte-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835803c78dffbe2df0fb5b5.webp</url>
      <title>Humacyte Inc</title>
      <link>https://6ix.com/company/humacyte-inc</link>
    </image>
    <item>
      <title>Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-to-host-virtual-kol-event-to-discuss-atev-for-arteriovenous-av-access-for-hemodialysis-patients-on-april-28-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-to-host-virtual-kol-event-to-discuss-atev-for-arteriovenous-av-access-for-hemodialysis-patients-on-april-28-2026</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
      <description>DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, April 28, 2026 at 8:00 AM ET featuring Prabir Roy-Chaudhury MD, PhD, FASN (University of North Carolina (UNC) Kidney Center, Salisbury VA Medical Center), and Mohamad A. Hussain, MD, PhD, RPVI, FAHA</description>
    </item>
    <item>
      <title>Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-expands-commercial-and-business-development-opportunities-through-realignment-of-ex-us-rights-to-symvessr</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-expands-commercial-and-business-development-opportunities-through-realignment-of-ex-us-rights-to-symvessr</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 GMT</pubDate>
      <description>- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding international and indication-specific rights to Symvess – - Existing terms related to U.S. distribution of Symvess remain unchanged DURHAM, N.C., April 24, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissu</description>
    </item>
    <item>
      <title>Humacyte Appoints Jim Mercadante as Chief Commercial Officer</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-appoints-jim-mercadante-as-chief-commercial-officer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-appoints-jim-mercadante-as-chief-commercial-officer-1</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader</description>
    </item>
    <item>
      <title>Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-israeli-ministry-of-health-acceptance-of-marketing-authorization-application-for-symvessr-for-vascular-trauma-repair</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-israeli-ministry-of-health-acceptance-of-marketing-authorization-application-for-symvessr-for-vascular-trauma-repair</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
      <description>- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that its Marketing Authorization Application (MAA) seeking approval of the acellular ti</description>
    </item>
    <item>
      <title>Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Fri, 27 Mar 2026 11:00:00 GMT</pubDate>
      <description>- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Submitted of a Marketing Authorization Application with the Israel Ministry of Health - - U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim</description>
    </item>
    <item>
      <title>Humacyte Appoints Rick McElheny as Senior Vice President of Business Development</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-appoints-rick-mcelheny-as-senior-vice-president-of-business-development</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-appoints-rick-mcelheny-as-senior-vice-president-of-business-development</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - - He will work with the</description>
    </item>
    <item>
      <title>Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-to-announce-2025-fourth-quarter-and-year-end-financial-results-and-provide-business-update-on-march-27-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-to-announce-2025-fourth-quarter-and-year-end-financial-results-and-provide-business-update-on-march-27-2026</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 GMT</pubDate>
      <description>DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 F</description>
    </item>
    <item>
      <title>Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-receives-symvessr-purchase-commitment-for-clinical-evaluation-and-outreach-program-in-the-kingdom-of-saudi-arabia</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-receives-symvessr-purchase-commitment-for-clinical-evaluation-and-outreach-program-in-the-kingdom-of-saudi-arabia</guid>
      <pubDate>Thu, 19 Mar 2026 12:31:00 GMT</pubDate>
      <description>- Purchase commitment is for a minimum of $1.475 million of Symvess product -DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase commitment of $1.475 million of the Symvess acellular tissue engineered vessel to facilitate a clinical evaluation and outreach program in hospitals wit</description>
    </item>
    <item>
      <title>Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-inc-announces-pricing-of-dollar20-million-registered-direct-offering-of-common-stock</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-inc-announces-pricing-of-dollar20-million-registered-direct-offering-of-common-stock</guid>
      <pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
      <description>Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as</description>
    </item>
    <item>
      <title>Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-submits-marketing-authorization-application-for-symvessr-in-israel-for-vascular-trauma-repair</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-submits-marketing-authorization-application-for-symvessr-in-israel-for-vascular-trauma-repair</guid>
      <pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
      <description>- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - - Preparation is</description>
    </item>
    <item>
      <title>Humacyte To Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-to-participate-in-upcoming-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-to-participate-in-upcoming-investor-conferences</guid>
      <pubDate>Mon, 02 Mar 2026 13:00:00 GMT</pubDate>
      <description>DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company’s management team will be participating in the following investor conferences during the month of March. TD Cowen 46th Annual Healthcare ConferencePresentation: Wednesday March 4, 2026, 10:30-11:00 am Eastern TimeWebcast Link: Click Here Barclays 28th</description>
    </item>
    <item>
      <title>Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-presentation-of-symvessr-long-term-safety-and-efficacy-results-at-vess-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-presentation-of-symvessr-long-term-safety-and-efficacy-results-at-vess-meeting</guid>
      <pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
      <description>- Data presented at Annual Winter Meeting 2026 for the Vascular &amp; Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked structural failures - - Long-term durability results showed no dilatation nor narrowing of Symvess diameter out to 36 months - DURHAM, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company</description>
    </item>
    <item>
      <title>Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-u-department-defense-130000958</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-u-department-defense-130000958</guid>
      <pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
      <description>DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries. The FY20</description>
    </item>
    <item>
      <title>Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-hospital-charge-data-130000315</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-hospital-charge-data-130000315</guid>
      <pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
      <description>- Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient respectively – - Humacyte’s Symvess® has consistently demonstrated low rates of infection and high rates of limb salvage – DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform compan</description>
    </item>
    <item>
      <title>Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-planned-marketing-authorization-130000789</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-planned-marketing-authorization-130000789</guid>
      <pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
      <description>- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned - DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it plans to file a Marketing Authorization Ap</description>
    </item>
    <item>
      <title>Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-publication-long-term-130000266</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-publication-long-term-130000266</guid>
      <pubDate>Mon, 22 Dec 2025 13:00:00 GMT</pubDate>
      <description>- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit - DURHAM, N.C., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing</description>
    </item>
    <item>
      <title>Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-credit-facility-77-130000480</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-credit-facility-77-130000480</guid>
      <pubDate>Tue, 16 Dec 2025 13:00:00 GMT</pubDate>
      <description>DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to $77.5 million in principal amount of new financing. The credit agreement, which has a term of four years, includes an initial tran</description>
    </item>
    <item>
      <title>Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-presentations-veithsymposium-highlighting-130000356</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-presentations-veithsymposium-highlighting-130000356</guid>
      <pubDate>Thu, 20 Nov 2025 13:00:00 GMT</pubDate>
      <description>– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – Positive outcomes for dialysis patients suffering from Steal syndrome who were treated with the ATEV – – Additional presentations report durable two-year outcomes for patients treated in Ukraine conflict, superior two-year outcomes for female dialysis patients, and results for patients treated with t</description>
    </item>
    <item>
      <title>Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-six-presentations-scheduled-130000202</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-six-presentations-scheduled-130000202</guid>
      <pubDate>Thu, 13 Nov 2025 13:00:00 GMT</pubDate>
      <description>DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six presentations on the Company’s acellular tissue engineered vessel (ATEV™) that are scheduled for the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques And Horizons (VEITHsymposium), to be held November 18-22, 2025 in New York, NY.</description>
    </item>
    <item>
      <title>Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/humacyte-inc/news/humacyte-announces-third-quarter-2025-120000903</link>
      <guid isPermaLink="true">https://6ix.com/company/humacyte-inc/news/humacyte-announces-third-quarter-2025-120000903</guid>
      <pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
      <description>- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations - - Conference call today at 8:00 am ET - DURHAM, N.C.,</description>
    </item>
  </channel>
</rss>